Insider Transactions in Q1 2024 at Regenxbio Inc. (RGNX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 19
2024
|
Vittal Vasista Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,041
+7.52%
|
$60,123
$3.76 P/Share
|
|
Mar 14
2024
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
15,000
-3.55%
|
$315,000
$21.86 P/Share
|
|
Mar 14
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+3.42%
|
$45,000
$3.76 P/Share
|
|
Mar 05
2024
|
Steve Pakola Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,878
-10.73%
|
$360,584
$28.36 P/Share
|
|
Mar 05
2024
|
Steve Pakola Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,878
+9.69%
|
$283,316
$22.25 P/Share
|
|
Feb 14
2024
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
15,000
-1.79%
|
$240,000
$16.67 P/Share
|
|
Feb 14
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+3.42%
|
$45,000
$3.76 P/Share
|
|
Jan 16
2024
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
45,000
-9.93%
|
$675,000
$15.18 P/Share
|
|
Jan 16
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+9.04%
|
$135,000
$3.76 P/Share
|
|
Jan 03
2024
|
Steve Pakola Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
17,237
-13.85%
|
$293,029
$17.39 P/Share
|
|
Jan 02
2024
|
Curran Simpson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,462
+23.77%
|
-
|
|
Jan 02
2024
|
Curran Simpson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,120
-8.73%
|
$138,040
$17.95 P/Share
|
|
Jan 02
2024
|
Olivier Danos Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,462
+23.55%
|
-
|
|
Jan 02
2024
|
Olivier Danos Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,410
-8.87%
|
$142,970
$17.95 P/Share
|
|
Jan 02
2024
|
Steve Pakola Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,051
+20.48%
|
-
|
|
Jan 02
2024
|
Steve Pakola Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,385
-10.11%
|
$176,545
$17.95 P/Share
|
|
Jan 02
2024
|
Vittal Vasista Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,026
+6.61%
|
-
|
|
Jan 02
2024
|
Vittal Vasista Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,534
-2.11%
|
$77,078
$17.95 P/Share
|
|
Jan 02
2024
|
Patrick J. Christmas Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,615
+23.02%
|
-
|
|
Jan 02
2024
|
Patrick J. Christmas Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,893
-8.86%
|
$134,181
$17.95 P/Share
|
|
Jan 02
2024
|
Kenneth T. Mills |
BUY
Grant, award, or other acquisition
|
Direct |
64,103
+13.58%
|
-
|
|
Jan 02
2024
|
Kenneth T. Mills |
SELL
Payment of exercise price or tax liability
|
Direct |
11,357
-3.2%
|
$193,069
$17.95 P/Share
|